Although it is well accepted that HAS2-AS1 works as a cis epigenetic regulator of HAS2 in aortic smooth muscle cells (AoSMCs) [72,128], this mechanism of action seems to be invalid in breast cancer. Here, HAS2 is linked to breast carcinoma.